TYRA vs. AXSM, MRUS, RARE, INSM, HCM, BHVN, PBH, ARWR, XENE, and CORT
Should you be buying Tyra Biosciences stock or one of its competitors? The main competitors of Tyra Biosciences include Axsome Therapeutics (AXSM), Merus (MRUS), Ultragenyx Pharmaceutical (RARE), Insmed (INSM), HUTCHMED (HCM), Biohaven (BHVN), Prestige Consumer Healthcare (PBH), Arrowhead Pharmaceuticals (ARWR), Xenon Pharmaceuticals (XENE), and Corcept Therapeutics (CORT). These companies are all part of the "pharmaceutical preparations" industry.
Axsome Therapeutics (NASDAQ:AXSM) and Tyra Biosciences (NASDAQ:TYRA) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, risk, community ranking, analyst recommendations, dividends, media sentiment, institutional ownership and profitability.
In the previous week, Axsome Therapeutics had 4 more articles in the media than Tyra Biosciences. MarketBeat recorded 9 mentions for Axsome Therapeutics and 5 mentions for Tyra Biosciences. Axsome Therapeutics' average media sentiment score of 1.28 beat Tyra Biosciences' score of 0.39 indicating that Tyra Biosciences is being referred to more favorably in the news media.
Axsome Therapeutics currently has a consensus target price of $121.92, suggesting a potential upside of 66.03%. Tyra Biosciences has a consensus target price of $23.50, suggesting a potential upside of 44.88%. Given Tyra Biosciences' stronger consensus rating and higher probable upside, equities analysts clearly believe Axsome Therapeutics is more favorable than Tyra Biosciences.
Axsome Therapeutics received 405 more outperform votes than Tyra Biosciences when rated by MarketBeat users. Likewise, 68.67% of users gave Axsome Therapeutics an outperform vote while only 62.07% of users gave Tyra Biosciences an outperform vote.
Tyra Biosciences has lower revenue, but higher earnings than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Tyra Biosciences, indicating that it is currently the more affordable of the two stocks.
Axsome Therapeutics has a beta of 1.13, indicating that its share price is 13% more volatile than the S&P 500. Comparatively, Tyra Biosciences has a beta of 1.08, indicating that its share price is 8% more volatile than the S&P 500.
81.5% of Axsome Therapeutics shares are held by institutional investors. Comparatively, 84.1% of Tyra Biosciences shares are held by institutional investors. 22.4% of Axsome Therapeutics shares are held by company insiders. Comparatively, 15.4% of Tyra Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Tyra Biosciences has a net margin of 0.00% compared to Tyra Biosciences' net margin of -118.07%. Axsome Therapeutics' return on equity of -28.61% beat Tyra Biosciences' return on equity.
Summary
Axsome Therapeutics beats Tyra Biosciences on 9 of the 17 factors compared between the two stocks.
Get Tyra Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for TYRA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TYRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Tyra Biosciences Competitors List
Related Companies and Tools
